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Abstract
Resequencing is an emerging tool for identification of rare disease-associated mutations. Rare mutations are difficult to tag
with SNP genotyping, as genotyping studies are designed to detect common variants. However, studies have shown that
genetic heterogeneity is a probable scenario for common diseases, in which multiple rare mutations together explain a
large proportion of the genetic basis for the disease. Thus, we propose a weighted-sum method to jointly analyse a group
of mutations in order to test for groupwise association with disease status. For example, such a group of mutations may
result from resequencing a gene. We compare the proposed weighted-sum method to alternative methods and show that it
is powerful for identifying disease-associated genes, both on simulated and Encode data. Using the weighted-sum method,
a resequencing study can identify a disease-associated gene with an overall population attributable risk (PAR) of 2%, even
when each individual mutation has much lower PAR, using 1,000 to 7,000 affected and unaffected individuals, depending
on the underlying genetic model. This study thus demonstrates that resequencing studies can identify important genetic
associations, provided that specialised analysis methods, such as the weighted-sum method, are used.
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Introduction
New technologies allow sequencing of parts of the genome of
large groups of individuals [1], and hereby initiate the next
generation of large scale association studies. Resequencing studies
can directly identify millions of rare mutations in the genome, and
may therefore be able to identify disease-mutations that are not
tagged by panels of common SNPs [2]. Resequencing may thus
hold the key to detecting associations in the presence of genetic
heterogeneity, where the genetic component of disease-risk is
determined by multiple rare mutations, each with a low marginal
effect on disease-risk (i.e. low population attributable risk; PAR).
Recent studies support the hypothesis that multiple rare mutations,
each with a low marginal effect, may be a major player in genetic
determination of susceptibility for some complex diseases [3–13].
Examples of genetically heterogeneous diseases include cystic
fibrosis [14,15], colorectal cancer [16] and probably schizophrenia
[13]. Different genetic models may underlie genetic heterogeneity.
One possibility is that multiple different variants located across the
genome have independent influence on disease risk, such that each
variant explains only a small fraction of all affected individuals.
Another scenario is that the function of each haplotype of a gene is
destroyed if one (or more) lethal mutations occur on the haplotype.
In this manner, an individual must have at least one mutation on
each of the two haplotypes to be predisposed for the disease (see
the Recessive-Set model in Figure 1). In both of these models, the
marginal PAR of each mutation may be very low, even when the
disease is highly heritable.
Association studies using panels of common SNPs are well
suited for identifying variants each with a relatively high PAR,
whereas multiple rare variants, each with a small PAR, are difficult
to identify using these methods [17–24]. In cases where a single (or
very few) common variants are expected to be associated with a
disease, a variant-by-variant approach using the strongest
marginal signal for each tested variant may be beneficial (as
discussed in [25] and [26]). On the other hand, when multiple rare
mutations are expected to influence disease risk, an obvious
approach is to group the variants according to function, such as
genes, pathways and ultra conserved regions, and compare the
group counts rather than the counts for each variant in the group.
The rationale behind this grouping approach is that if many
different mutations in a group affect disease risk, it may be
beneficial to focus on the group rather than on each variant
individually.
The cohort allelic sums test (CAST) is an existing grouping
method in which the number of individuals with one or more
mutations in a group (e.g. gene) is compared between affected and
unaffected individuals [5,26,27]. An alternative method using a
grouping approach is the Combined Multivariate and Collapsing
(CMC) method [26]. In this method all rare variants are collapsed,
as in the CAST method, and the collapsed variants are treated as a
single common variant which is analysed together with the other
common variants using multivariate analysis [26]. In the CMC
version used in [26], rare variants are defined as those having a
minor allele frequency (MAF) of at most 1%.
In this study, we focus on a scenario in which a group of
multiple rare mutations has been identified. In functional regions,
one may choose to include only probable disease susceptibility
mutations (non-synonymous substitutions, frame shift mutations,
etc) in the group of mutations. Using only probable disease
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to non-associated variants may decrease. In this manner,
association studies of groups of rare probable disease-susceptibility
variants may be able to identify genetically heterogeneous
mutations, and hence complement genome-wide analysis of
common SNPs. Grouping of mutations according to functional
elements, such as genes, has the added advantage of focusing on
causal relations between genes and diseases, rather than just
identifying highly associated genomic regions. Furthermore, since
many (millions of) mutations are expected to be identified in a
resequencing study of thousands of individuals [28], grouping
lowers the burden of multiple testing.
We propose a weighted-sum method in which mutations are
grouped according to function (e.g. gene), and each individual is
scored by a weighted sum of the mutation counts. To test for an
excess of mutations in affected individuals, we use permutation of
disease status among affected and unaffected individuals. By using
permutation, the method adjusts for the weighting of the
mutations and the requirement that a mutation must be observed
to be included in the study. Note that permutation of disease status
results in correct type I error even in the presence of linkage
disequilibrium (LD) [29,30], although relatively low LD is
expected between rare variants [26,31,32].
The weighted-sum method deviates from the CAST method
[5,27] by weighting the variants differently when determining the
genetic load of an individual. By weighting the signals from each
mutation, the weighted sum method accentuates mutations that
are rare in the unaffected individuals, so that the test is not
completely dominated by common mutations. In the CAST
method, common variants will have a high impact on the group
signal, and if many common mutations are present in a group,
almost all individuals will have one or more mutations. To avoid
this effect it may be necessary to use a threshold on the mutation-
frequencies, as suggested in the CMC method [26]. A drawback of
such frequency thresholds is that it can be difficult to select them in
a biological meaningful way, and the outcome of the test will
depend on the selection of thresholds. In the weighted-sum
method we include mutations of all frequencies, but mutations are
weighted according to their frequency in the unaffected individ-
uals.
Methods
Weighted-Sum Method
The weighted-sum method compares the number of mutations
in a group of variants between samples of affected and unaffected
unrelated individuals. It is designed to identify an excess of
mutations in the affected individuals, compared to the unaffected
individuals. Each variant belongs to a group (gene, pathway, ultra
conserved area, etc.) and, for a group with L variants, the method
is comprised of the following steps:
(A) For each variant i (=1,…,L), we choose which allele of the
variant to consider as the mutation (usually this will be the
rarer allele, unless other information suggests that the
common allele may be implicated in disease susceptibility)
and calculate a weight
^ w wi~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ni:qi 1{qi ðÞ
p
,
where
qi~
mU
i z1
2nU
i z2
, ð1Þ
mi
U is the number of mutant alleles observed for variant i in
the unaffected individuals, ni
U is the number of unaffected
individuals genotyped for variant i, and ni is the total
number of individuals genotyped for variant i (affected and
unaffected).
The weight, ^ w wi, is the estimated standard deviation of the
total number of mutations in the sample (including affected
and unaffected individuals), under the null hypothesis of no
frequency differences between affected and unaffected
Author Summary
Resequencing is an emerging tool for the identification of
rare disease-associated mutations. Recent studies have
shown that groups of multiple rare mutations together can
explain a large proportion of the genetic basis for some
diseases. Therefore, we propose a new statistical method
for analysing a group of mutations in order to test for
groupwise association with disease status. We compare
the proposed weighted-sum method to alternative meth-
ods and show that it is powerful for identifying disease-
associated groups of mutations, both on computer-
simulated and real data. By using computer simulations,
we further show that resequencing a few thousand
individuals is sufficient to perform a genome-wide study
of all human genes, if the proposed method is used. This
study thus demonstrates that resequencing studies can
identify important genetic associations, provided that
specialised analysis methods, such as the proposed
weighted-sum method, are used.
Figure 1. Genetic models. Model descriptions and examples of predisposing genotypes are shown for the genetic models used. Lines symbolise
haplotypes and dots symbolise disease-risk mutations.
doi:10.1371/journal.pgen.1000384.g001
Weighted-Sum Method
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constructing the weighted-sum score; see (B) and (C) below.
We estimate qi according to the mutation-frequency in the
unaffected individuals only, rather than the frequency in the
combined population of affected and unaffected individuals.
We use this approach so that a true signal from an excess of
mutations in the affected individuals is not deflated by using
the total number of mutations in both affected and
unaffected individuals. By using a permutation-based test,
we account for using only the unaffected individuals when
scaling the mutation frequency, and we are hence able to
increase the power of detecting very rare disease-associated
mutations. The drawback of this approach is a higher
variance of the scaled mutation-frequency, and hence a loss
of power when the frequency of the mutation is high.
Adding one to the numerator and two to the denominator of
the frequency estimate, qi, avoids zero estimates which
would lead to numerical problems in the genetic score used
below, and is based on the Bayesian posterior-mean
estimate of a binomial proportion when using a uniform
prior.
(B) The genetic score of each individual j is calculated as
cj~
X L
i~1
Iij
^ w wi
,
where Iij is the number of mutations in variant i for
individual j. Under a general genetic model IijM{0,1,2}.
However, if a variant (or group) is known to act recessively
or dominantly IijM{0,1}, and the components of mi
UM{0,1}
accordingly in equation (1); in the recessive case only
homozygote mutants are assigned the value 1, and in the
dominant case both the heterozygote and homozygote
mutants are assigned the value 1.
(C) All individuals (affected and unaffected together) are ranked
according to their genetic scores (cj), and the sum of the
ranks for affected individuals is calculated as
x~
X
j[A
rank cj
  
,
where A is the population of affected individuals. Under the
null-hypothesis (no disease association) and the assumption
that the genotypes of the affected individuals are indepen-
dent, x is a sum of n
A independently and identically
distributed (i.i.d.) random variables, and is thus approxi-
mately normally distributed according to the central limit
theorem. Note that using ranking to determine x is
equivalent to the procedure in the Wilcoxon test [33].
(D) The affected/unaffected status is permuted among the
individuals, and steps (A)–(C) are repeated k times to sample
x1
*,…,xk
* under the null-hypothesis.
(E) The average (^ m m) and sample standard deviation (^ s s)o f
x1
*,…,xk
* are calculated and the standardized score-sum is
found as
z~
x{^ m m
^ s s
:
Under the null hypothesis, z has an approximately standard
normal distribution (see Figure S1 for an example). Thus, a
p-value for the association test can be obtained by
comparing z to the quantiles of the standard normal.
Alternatively a p-value can be found by using a standard
permutation test, where the p-value is found by (k0+1)/(k+1), and
k0 is the number of the k permutations that are at least as extreme
as x. In such a testing framework, the permuting routine can be
stopped if the estimated p-value (and its precision) reaches a
certain level; e.g. if the p-value, minus three times the estimated
standard deviation of the p-value, is above the significance
threshold. Such a permutation strategy may be as fast as the
approximation strategy, since fewer than 1000 permutations are
needed to reject the hypothesis of association in many cases.
Throughout this paper, the approximation strategy is used
because it runs fast for power simulations. Another reason for
using the approximation strategy (rather than standard permuta-
tion with a stopping rule) is to produce Uniform(0,1) distributed p-
values (under the null hypothesis; see Figure S2) for all the tests
conducted, which is preferred if further analyses of the p-values are
conducted in e.g. a pathway analysis. The standard permutation
approach can only produce uniformly distributed p-values under
the null hypothesis if no stopping rule is used, which is a
computationally expensive approach.
Whether using the approximation or standard permutation
strategy, permutation of the case-control labels maintains the LD
structure of the genetic data. Thus, the test is valid (i.e. has correct
false positive rate) whether or not the variants are in LD.
Power Simulations
The weighted-sum method is compared to the CAST, CMC,
and variant-by-variant methods, which were discussed in the
introduction and are described in more detail in Comparison with
other Methods. For each set of parameters, 100 datasets are
simulated, the four methods are applied, and the proportions of
significant outcomes are used as the power estimates. To mimic a
genome wide study of about 20,000 fairly independent human
genes, we calculate a p-value for each gene, and use a significance
threshold of 0.05/20000=2.5610
26 in all power simulations.
Genetic Models. Four genetic models are investigated (see
Figure 1). For the Recessive, Additive and Dominant models the
disease-related variants act independently, whereas for the
Recessive-Set model the outcome of a mutation at one variant
depends on the presence of a mutation at another variant (see
Figure 1). We do not sample Dominant-Set or Additive-Set
models, since in these models the heterozygote predisposes for
disease, and hence they perform like the Dominant and Additive
models respectively. We sample the variants independently for
simplicity and because rare variants are not expected to be in high
LD with the surrounding variants [31,32].
Frequency Spectra. For the Recessive, Additive and
Dominant models, we sampled the unaffected population
frequency spectrum of the mutations at each variant according
to Wright’s formula [34,35]:
fp ðÞ ~cpbs{1 ðÞ 1{p ðÞ
bN{1 ðÞ es 1{p ðÞ ,
where f(p) is the probability function of the mutation-probability p,
bS is the scaled mutation rate of disease mutations, bN is the scaled
back-mutation rate and s is the scaled selection rate [32]. The
constant c normalizes the integral of f(p) to 1. The frequency
spectrum for each variant is sampled with parameters for mildly
deleterious mutations, bS=0.001, bN =bS/3 and s=12, as
discussed by [32].
Weighted-Sum Method
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mutations are drawn with the same probability for each variant in
a group. The mutation probability is calculated such that the
probability (pM) that a haplotype contains at least one disease-risk
mutation is fixed in unaffected individuals. In concordance with
human resequencing studies we use pM=10% as baseline [5,16],
but we have investigated other values also.
Sampling Individuals. To control the PAR (population
attributable risk) of each group, and ensure that all variants have a
low effect, we sample each variant in a group using the same
marginal PAR (a), so that a is the group-PAR divided by the
number of disease-risk contributing variants (D-variants). Each
variant is sampled independently. The mutation probability in
unaffected individuals is sampled according to the frequency
spectrum described above, and the genotype probabilities in
unaffected individuals are calculated assuming Hardy-Weinberg
proportions. The odds ratio (r) of each genotype is calculated from
the genotype probability in the unaffected individuals (qU) using
r~
a
1{a ðÞ qU
z1,
and the genotype probability in the affected individuals (qA)i s
calculated as
qA~
rqU
1z r{1 ðÞ qU
:
See e.g. Ref. [36]. The population of affected and population of
unaffected individuals are sampled using qA and qU respectively.
We simulate n
A=1000 affected and n
U=1000 unaffected
individuals unless otherwise stated.
Disease-risk contributing variants and disease-risk
neutral variants. Because not all probable disease
susceptibility mutations (non-synonymous substitutions,
frameshift mutations etc.) contribute to disease-risk, we simulate
both disease-risk contributing variants (D-variants) and disease-risk
neutral variants (N-variants). Under all genetic models, the N-
variants are sampled with the same genotype probabilities in
affected and unaffected individuals, and the frequency spectrum of
mutations follows Wright’s formula.
It has been reported that about 70% of all rare missense
mutations are deleterious [4], but since not all deleterious
mutations necessarily contribute to disease-risk, we simulate 50%
D-variants as the baseline, but investigate other levels also (see
Results). As discussed in [32], a human gene may contain up to
1000 disease susceptibility variants, whereof only a part are
polymorphic in a given sample. Resequencing studies of the
coding parts of human genes suggest that 50 disease susceptibility
variants is a realistic level [5,7,16], and we therefore simulate
groups with 50 D-variants and 50 N-variants as the baseline, but
investigate other levels also (see Results).
Tested Variants. The mutation probabilities (p) can be very
low for some of the sampled variants. This means that some
variants contain no mutations in any of the sampled individuals,
and these variants are hence omitted in the tests.
Encode Data
To evaluate the weighted-sum method on rare variants with the
frequency-spectrum of a naturally occurring population, we used
resequencing data from the Encode III project (ftp://ftp.hgsc.bcm.
tmc.edu/pub/data/Encode). In the Encode III project ten 100 kb
Encode regions were resequenced in different human populations,
and all substitutions were identified (see http://www.hgsc.bcm.tmc.
edu/projects/human/). To mimic a disease-resequencing study, we
grouped all exonic variants of each Encode region, and compared
thenumberofrare variantsbetweenthe twolargest populations: the
African YRI population (120 individuals; including 60 individuals
from HapMap phase I and II) and the Central European CEU
population (119 individuals; including 60 individuals from HapMap
phase I and II). Only variants that passed the quality control filter
for the ENCODE III study were used (see http://www.hgsc.bcm.
tmc.edu/projects/human/). The genotype data were downloaded
as the ENCODE III draft release I (on August 11th, 2008), and the
‘‘Gencode Ref (encodeGencodeGeneKnownMar07)’’ track in the
UCSC Genome Browser [37] was used to define exon positions in
each ENCODE region. Exonic variations were reported for only
five of the ten ENCODE regions, and hence only these five regions
were used.
Comparison with Other Methods
The CAST method, as described in [27], corresponds to the
method used in [5]. In brief, for each group of variants, it
compares the number of individuals with one or more mutations
between affected and unaffected individuals, using a standard x
2
or Fisher exact test. In this study, we use the Fisher exact test
throughout to avoid bias due to distributional approximation.
In the variant-by-variant approach the genotype frequencies of
each variant are compared using the one-sided Fisher’s exact test,
and the significance level of the group is found by Dunn-Sidak
correction [38] of the smallest p-value in the group. Note that the
Dunn-Sidak correction is very similar to the Bonferroni correction,
as the Bonferroni correction is an approximation of the Dunn-
Sidak correction. Whereas the Bonferroni correction is slightly
conservative for independent tests (such as the independent
variants in the power simulations), the Dunn-Sidak correction
has the benefit of being exact.
The CMC method is implemented according to the description
in [26]. In brief, for the CMC method all rare variants are
collapsed, as in the CAST method, and the collapsed variants are
treated as a single common variant which is analysed together with
the other common variants using multivariate analysis [26]. We
used the Fisher product method [42,43] for multivariate analysis,
rather than the Hotelling’s T
2 method, because it allows for one-
sided testing, and hence allowed a fair comparison for the CMC
method. Note that if a two-sided test were used for the CMC
method, the power estimates would then have been too low
compared to the variant-by-variant and weighted-sum methods.
The weighted-sum method is implemented as described above,
using k=1000 permutations in step C. In all power simulations
IijM{0,1,2} is used in step B (even when the dataset is simulated
under a recessive or dominant model).
Results
Proportion of Variants Containing Mutations
The mutation frequencies are sampled according to Wright’s
formula (see Methods), and hence mutations are very rare for
some variants. Using 1000 affected and 1000 unaffected
individuals, mutations are on average observed at only 49.4% of
the variants (sd: 4.9%). This means that when e.g. 100 variants are
sampled, on average 49.4 variants contain at least one mutation,
and are hence tested for association. This level is in concordance
with the level from human resequencing studies [5,7,16].
Power versus PAR
Under the baseline parameter settings (see Methods) it is seen that
the CMC method, as reported in [26], has better performance than
Weighted-Sum Method
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method has even better performance (Figure 2). The weighted-sum
method identifies groups with a PAR of 10%, with at least 80%
power, for all genetic models (Figure 2). To investigate whether the
weighted-sum method is robustunder other model parameters,we fix
the group PAR at 10%, and vary the other parameters one by one.
Figure 2. Power versus PAR of group. The power of the investigated methods is shown for different levels of group-PAR. The power simulations
were performed using n
A=n
U=1000 individuals, 50 D-variants, 50 N-variants and pM=10%.
doi:10.1371/journal.pgen.1000384.g002
Weighted-Sum Method
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The number of variants that contribute to the disease-risk (D-
variants) determines the marginal PAR of each variant in the
group, such that a low number of D-variants yields a high
marginal PAR. Accordingly, all investigated methods perform well
when the number of D-variants is low, and hence the marginal
PAR is high (Figure 3). When the number of D-variants rises, and
hence the marginal PAR of each variant drops, the power to
identify a disease-group falls (Figure 3). For the weighted-sum
method, the effect of the number of D-variants depends on the
genetic model. For the recessive models, it is able to identify even
large groups of variants, whereas it is more sensitive to the number
of D-variants when the heterozygote contributes to disease-risk
(Figure 3).
The proportion of D-variants likewise influences the power.
Under the Recessive-Set model, both the CAST and the CMC
methods perform well when a reasonably high proportion of the
variants contribute to disease-risk, whereas both the variant-by-
variant and the CAST method are unable to identify disease-
groups under the other scenarios (Figure 4). On the other hand,
the weighted-sum method is generally robust to a low proportion
of D-variants in the group, but a higher proportion of D-variants
yields higher power (Figure 4).
Note that the probability of mutant-haplotypes (pM)i n
unaffected individuals under the Recessive-Set model does not
have a large impact on the power (Figure S3).
Number of Individuals Needed
The number of individuals needed to identify a disease-
associated group depends strongly on the underlying genetic
scenario. With n=n
A=n
U=1000 individuals, a group with a PAR
of 1% can be identified under the Recessive-Set model, while a
group with a PAR of 5%–10% can be identified under the other
models. A study with n=7000 individuals can identify a group
with a PAR of 2% under all genetic models (Table 1; see Tables S1
and S2 for equivalent tables for the CMC and CAST methods).
Encode Data
To cover a scenario where the mutation-frequencies are
distributed according to a natural existing population, we used
resequencing data from 120 individuals from the African YRI
population and 119 individuals from the Central European CEU
population. In this example, we test for overrepresentation of rare
exonic variants in the YRI population compared to the CEU
population in each Encode region. Such an overrepresentation is
expected since the YRI population generally shows higher
diversity than the CEU population [39], and hence more rare
variants are expected. Exonic variants are grouped for each
ENCODE region, to mimic a disease-resequencing study like the
ones reported in human resequencing studies [5,7,16]; as a result,
5 groups of 2–72 polymorphic variants are obtained (see Table 2).
As with the simulated data, the weighted-sum method generally
shows higher power than the alternative methods to identify an
excess of rare variants in the Encode data (Table 2).
Table 2 shows that large groups of variants generally yield lower
p-values than small groups. This is expected in the case of
heterogeneity, where inclusion of more variants will lead to a
stronger combined signal, and hence a lower p-value.
Computational Speed
In the current un-optimized implementation of the weighted-
sum method, a genome wide analysis of 20,000 groups, with 50
polymorphic variants each, using n
A=n
U=1000 individuals can
be completed in approximately 600 CPU hours on a standard
stand-alone machine (Intel Pentium Dual 2 GHz, 2GB RAM).
When the number of permutations (k) is 500 instead of 1000, the
results are unaffected (results not shown) but the computing time is
halved, however since the test is fast we use k=1000 in this study.
Note that the computation time is linear in number of individuals
and number of permutations (see Table S3).
Discussion
In this work, we propose a specialised method to identify multiple
rare mutations underlying a genetically heterogeneous disease.
Analysis of real data and power simulations show that the proposed
weighted-sum method performs very well compared to existing
methods. This demonstrates that the use of specialised analytical
methods can improve power to identify genetic components of
complex (genetically heterogeneous) diseases. On the other hand, it
must be kept in mind that the power of such specialisation is at the
cost of generality, and therefore the methods must be used in
combination with other strategies covering other biological
scenarios such as the common variant common disease scenario.
It must further be noticed that all methods using the grouping
approach (i.e. CMC, CAST and weighted-sum) are sensitive to
misclassification of which allele is treated as the mutation (i.e.
disease-related allele). If disease-related alleles from some variants
are grouped with wild-type alleles from other variants it may hide a
true signal. As stated in the Background section, it may be natural to
treat e.g. non-synonymous substitutions, frame shift indels and very
rare alleles as mutations, but when there is no information to classify
the alleles, grouping methods may not be useful. Instead the idea
from the CMC method can be used, such that the variants that can
be grouped are analysed with a grouping statistic (e.g. the weighted-
sum method), and all other variants are analysed variant by variant
or by multivariate analysis.
The weighted-sum method is designed for resequencing data,
since this technology allows rare mutations to be observed directly.
The use of inferred haplotypes from tag SNP studies is a current
approach to evaluation of unobserved variants, but this approach
fails when the unobserved variants are rare; the tag SNP approach
is hence not suited for the scenario of multiple rare disease-
mutations [2]. Alternatively, familial linkage studies are a strategy
to identify mutations underlying genetically heterogeneous diseas-
es, but when the marginal effect of each mutation is low, it may be
difficult to obtain a sufficient number of affected individuals to
detect a disease association [40,41].
The weighted-sum method can be adapted to a wide range of
study designs, by e.g. the following: (A) Using the posterior
probability of each genotype rather than the most probable
genotype. (B) Analysing mutations in conserved areas by weighting
each mutation according to the measure of conservation; this is an
extension of the conservation base selection criterion from [7]. (C)
Analysing continuous traits by testing for correlation between
genetic ranks (or scores) and the trait measure. Furthermore, the
weighted-sum method can be used for other types of data that can
be grouped according to function. Such data include for example
methylation measures, where multiple regions/sites can be
methylated in promotor regions (i.e. the CpG islands). Note that
ranking can be omitted in the test procedure, so the test statistic is
the sum of the genetic scores (ci) of all affected individuals, rather
than the sum of ranks. In the tests performed in this study, the two
procedures yield very similar results (results not shown), but we
prefer to use the ranking procedure because it is robust to outliers.
The mutation weights (^ w wi) can be chosen in an infinite
number of ways. We suggest using the estimated standard
Weighted-Sum Method
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(including affected and unaffected individuals), under the null
hypothesis of no frequency differences between affected and
unaffected individuals. This choice of weight ensures that all
variants in a group contribute equally to the weighted sum,
under the null hypothesis. The weight of each mutation is
Figure 3. Power versus number of D-variants. The power of the investigated methods is shown for different number of D-variants (disease-risk
contributing variants). The power simulations were performed using n
A=n
U=1000 individuals, 50% D-variants, group PAR of 10% and pM=10%.
Note that the jump in the power for the CMC method under the Recessive-set model occurs because a low number of variants yields a high allele-
frequency of each variant, and the variants are hence not grouped by the CMC method.
doi:10.1371/journal.pgen.1000384.g003
Weighted-Sum Method
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individuals only. In this way, a mutation which is common
among unaffected individuals has lower weight than a mutation
which is rare among the unaffected individuals. If further
information about the mutations is available, it may be
incorporated in the weights. Such information could include
the estimated impact of a mutation or a measure of
conservation of the surrounding region (as discussed above).
Figure 4. Power versus proportion of D-variants. The power of the investigated methods is shown for different proportions of D-variants
(disease-risk contributing variants). The power simulations were performed using n
A=n
U=1000 individuals, 50 D-variants, group PAR of 10% and
pM=10%.
doi:10.1371/journal.pgen.1000384.g004
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way is to use the pathway as a group, and run the test on the entire
pathway. On the other hand, for large pathways, it may be
beneficial to use a method that allows a gene with a strong signal
to have a high impact on the combined pathway test-statistic (T). If
a pathway contains G non-overlapping genes, a method to do this
is to use the weighted-sum method on each gene, and combine
the resulting p-values (p1,…,pG) with the Fisher product test
statistic
T~{2
X G
g~1
ln pg
  
:
Since p1,…,pG are i.i.d. uniformly(0,1) distributed under the null-
hypothesis, T is x
2-distributed with 2G degrees of freedom, and
can be evaluated accordingly [42,43]. This method allows for fast
analysis of different pathways, using the results from the gene-
analysis, and can thereby assist in the functional analysis of a
disease association study.
Simulating inheritance of a genetically heterogeneous disease
can be performed in different ways. To ensure that all variants
have a low effect, we have chosen to simulate all variants within a
group with the same PAR. An alternative scenario is to simulate all
variants, in a group, with the same relative risk (RR), and let the
PAR vary according to the mutation-frequency. Under this
scenario, a single, or few, common mutations may carry a large
part of the total risk, and this scenario is hence equivalent to a
scenario with a single, or few, disease-contributing variants. A few
common variants carrying a relatively large risk is exactly the what
studies using panels of SNPs are designed for, and our focus has
therefore been on scenarios where the disease risk can not be
explained by a few variants. Note further that all investigated
methods are able to identify cases where a few mutations carry a
large part of the total risk (see Figure 3). We have further included
the comparison of the Encode populations, to cover a scenario
where the mutation-frequencies are distributed according to an
actual population.
In summary, we show that the weighted-sum method is
powerful for identifying multiple rare mutations underlying
Table 1. Number of individuals needed to identify a disease-associated group.
Recessive-Set
n
500 1000 2000 4000 7000 10000
Group PAR 1 2 99 100 100 100 100
21 2 100 100 100 100 100
51 8 100 100 100 100 100
10 63 100 100 100 100 100
Recessive
n
500 1000 2000 4000 7000 10000
Group PAR 1 0 0 1 18 66 95
20 1 2 4 95 100 100
50 80 100 100 100 100
10 0 100 100 100 100 100
Additive
n
500 1000 2000 4000 7000 10000
Group PAR 1 0 0 0 2 11 29
20 0 4 2 9 88 100
50 8 84 100 100 100
10 1 90 100 100 100 100
Dominant
n
500 1000 2000 4000 7000 10000
Group PAR 1 0 0 0 2 13 35
20 0 5 3 3 93 100
50 1 1 85 100 100 100
10 0 90 100 100 100 100
The power (in %) of the weighted-sum method is shown for different numbers of individuals n=n
A=n
U, and different levels of group PAR (in %). Combinations with at
least 80% power are shown in bold. The power simulations were performed using 50 D-variants, 50 N-variants and pM=10%.
doi:10.1371/journal.pgen.1000384.t001
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1000 affected and 1000 unaffected individuals are sufficient to
identify e.g. a gene with a PAR of only 1%, corresponding to an
odds ratio of 1.1. These findings thus demonstrate that resequen-
cing studies have the potential to identify important genetic
associations, provided specialised analysis methods are used.
Supporting Information
Figure S1 Distribution of permuted ranked score sums x1
*,…,xk
*
for ENCODE region ENm010. The distribution of the ranked
score sums (x1
*,…,xk
*) from the k=1000 permutations is consistent
with normality, as the points follow the line of identity. The data
set is an example containing all exonic variants with MAF#5%
from the ENCODE III project, region ENm010 (see Encode Data
in Methods for details). The permuted data (x1
*,…,xk
*) show
similar Gaussian properties for the other tested scenarios (data not
shown).
Found at: doi:10.1371/journal.pgen.1000384.s001 (.006 MB TIF)
Figure S2 Distribution of p-values under the null hypothesis of
no disease association. The distribution of 20,000 p-values under
the null hypothesis is consistent with a uniform distribution, as the
points follow the line of identity. The simulations were performed
using n
A=n
U=1000 individuals and 100 N-variants.
Found at: doi:10.1371/journal.pgen.1000384.s002 (.005 MB TIF)
Figure S3 Power versus probability of mutant-haplotypes in the
Recessive-Set model. The power of the investigated methods is
Table 2. Tests for excess of rare exonic variants in the YRI population compared to the CEU population.
MAF cut-off
1% 2% 3% 4% 5%
ENm010
# variants 42 (30/13) 57 (40/18) 66 (48/20) 69 (51/20) 72 (54/20)
Weighted-sum 2.72610
23 2.22610
23 5.75610
26 5.76610
27 5.44610
212
CMC 2.53610
23 0.01 0.10 0.05 0.01
CAST 2.53610
23 0.01 5.34610
24 4.66610
25 1.21610
29
Variant-by-variant 1.00 1.00 1.00 0.37 0.12
ENr133
# variants 40 (23/20) 43 (26/20) 48 (30/21) 49 (30/22) 51 (32/23)
Weighted-sum 0.41 0.06 3.49610
24 3.22610
23 7.28610
24
CMC 0.51 0.11 0.04 0.04 3.22610
23
CAST 0.51 0.11 1.68610
23 0.03 5.89610
23
Variant-by-variant 1.00 1.00 0.69 0.34 0.04
ENr232
# variants 19 (11/8) 23 (15/9) 28 (19/11) 28 (19/11) 29 (20/11)
Weighted-sum 0.32 0.05 0.02 0.02 4.99610
24
CMC 0.42 0.22 0.20 0.20 6.69610
23
CAST 0.42 0.10 0.07 0.07 4.82610
23
Variant-by-variant 1.00 1.00 0.19 0.19 0.02
ENr123
# variants 4 (3/1) 5 (4/1) 5 (4/1) 5 (4/1) 6 (5/2)
Weighted-sum 0.73 0.21 0.21 0.21 0.97
CMC 0.88 0.35 0.35 0.35 0.57
CAST 0.88 0.35 0.35 0.35 0.98
Variant-by-variant 1.00 1.00 1.00 1.00 0.08
ENr213
# variants 2 (0/2) 2 (0/2) 3 (1/3) 3 (1/3) 4 (2/4)
Weighted-sum 0.93 0.93 0.51 0.51 0.79
CMC 1.00 1.00 0.57 0.57 0.72
CAST 1.00 1.00 0.64 0.64 0.86
Variant-by-variant 1.00 1.00 1.00 1.00 1.00
For each Encode region, we test whether rare exonic variants are overrepresented in the African (YRI) population compared to the central European (CEU) population.
To mimic studies of rare variants, five different minor allele frequency (MAF) cut-off values (1%–5%) are used; all variants with a MAF over the cut-off value are omitted
in the analysis. For each set of variants, the number of tested variants is reported along with the number of variants that are only polymorphic in the YRI population (the
first number in the parenthesis), and the number of variants that are only polymorphic in the CEU population (the second number in the parenthesis). Below the
number of variants, p-values from the investigated methods are reported. It is seen that the proposed test yields lower p-values than the alternative tests in nearly all
cases where the rare variants are significantly overrepresented in the YRI population. The only exception is for the ENm010 region with MAF cut-off at 1%; in that case,
the weighted-sum method yields a slightly higher p-value than the CMC and CAST methods.
doi:10.1371/journal.pgen.1000384.t002
Weighted-Sum Method
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The power simulations were performed using n
A=n
U=1000
individuals, 50 D-variants, 50 N-variants and group PAR of 10%.
Found at: doi:10.1371/journal.pgen.1000384.s003 (0.6 MB TIF)
Table S1 Number of individuals needed to identify a disease-
associated group, using the CMC method. The power (in %) of the
CMC method is shown for different number of individuals
n=n
A=n
U, and different levels of group PAR (in %). The power
simulations were performed using 50 D-variants, 50 N-variants
and pM=10%.
Found at: doi:10.1371/journal.pgen.1000384.s004 (0.02 MB PDF)
Table S2 Number of individuals needed to identify a disease-
associated group, using the CAST method. The power (in %) of
the CAST method is shown for different number of individuals
n=n
A=n
U, and different levels of group PAR (in %). The power
simulations were performed using 50 D-variants, 50 N-variants
and pM=10%.
Found at: doi:10.1371/journal.pgen.1000384.s005 (0.02 MB PDF)
Table S3 Computational Speed. The computation time (in CPU
hours) is shown for testing 20,000 groups with 50 polymorphic
variants each, using the weighted-sum method. The speed
computation is done for different number of individuals
(n=n
A=n
U), and different number of permutations (k). It is seen
that the computation time is linear in the number of individuals
and in the number of permutations.
Found at: doi:10.1371/journal.pgen.1000384.s006 (0.01 MB PDF)
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